2016
Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial
Xu R, Shimizu F, Hovinga K, Beal K, Karimi S, Droms L, Peck KK, Gutin P, Iorgulescu JB, Kaley T, DeAngelis L, Pentsova E, Nolan C, Grommes C, Chan T, Bobrow D, Hormigo A, Cross JR, Wu N, Takebe N, Panageas K, Ivy P, Supko JG, Tabar V, Omuro A. Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. Clinical Cancer Research 2016, 22: 4786-4796. PMID: 27154916, PMCID: PMC5050072, DOI: 10.1158/1078-0432.ccr-16-0048.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenzazepinesBrain NeoplasmsChemoradiotherapyFemaleGliomaHumansMaleMaximum Tolerated DoseMiddle AgedNeoplasm Recurrence, LocalNeoplastic Stem CellsNeovascularization, PathologicReceptors, NotchConceptsRecurrent tumorsCancer-initiating cell populationGamma secretase inhibitor RO4929097Blood-brain barrier disruptionBlood-brain barrier penetrationDose-limiting toxicityNotch intracellular domainPotential therapeutic optionSignificant decreaseRelative plasma volumeHigh-grade gliomasTumor explant culturesNotch pathwayI trialDismal prognosisTherapeutic optionsBarrier disruptionDrug exposureAnaplastic astrocytomaAngiogenic factorsTumor tissueAntiangiogenic roleTarget modulationDrug penetrationPerfusion MRI
2014
Current Role of Anti-Angiogenic Strategies for Glioblastoma
Thomas AA, Omuro A. Current Role of Anti-Angiogenic Strategies for Glioblastoma. Current Treatment Options In Oncology 2014, 15: 551-566. PMID: 25173555, DOI: 10.1007/s11864-014-0308-2.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntineoplastic AgentsBiomarkersBrain NeoplasmsGlioblastomaHumansNeovascularization, PathologicPrognosisTreatment OutcomeConceptsProgression-free survivalPhase III trialsIII trialsOverall survivalRecurrent diseaseStandard chemoradiotherapyClinical benefitAnti-vascular endothelial growth factor monoclonal antibodyCognitive declineSimilar progression-free survivalToxicity of bevacizumabAddition of bevacizumabPhase II trialSevere neurologic symptomsFactor monoclonal antibodyNew drug combinationsAnti-angiogenic therapyReduced vascular permeabilityQuality of lifeUnquestionable clinical benefitObserved cognitive declineBevacizumab armOS trendsCorticosteroid useFree survival